VERA Vera Therapeutics
Price Chart
Executive Summary
Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pulling the analysis forward to Q3 2026 (from 2027). This accelerates the potential path to full approval, with an sBLA submission planned for Q4 2026. The PDUFA date for accelerated approval remains July 7, 2026.
Actionable Insight
The accelerated eGFR analysis and sBLA timeline de-risks the path to full approval and increases the probability of an earlier commercial launch. Traders should watch for the PDUFA date on July 7, 2026, and the eGFR results in Q3 2026. Positive outcomes could drive substantial upside.
Key Facts
- FDA aligned on revised ORIGIN 3 eGFR analysis plan, results now expected Q3 2026 (pulled forward from 2027).
- Pending positive eGFR results, Vera plans to submit sBLA for full approval in Q4 2026.
- PDUFA date for accelerated approval of atacicept in IgAN remains July 7, 2026.
- Atacicept has Breakthrough Therapy Designation for IgAN.
- ORIGIN Phase 2b and Phase 3 trials met primary endpoints with statistically significant proteinuria reduction and eGFR stabilization.
Financial Impact
Accelerated full approval timeline could bring atacicept to market earlier, potentially adding hundreds of millions in peak sales. Vera's market cap is $2.4B; a positive eGFR readout and subsequent full approval could significantly increase valuation.
Risk Factors
- FDA may not approve accelerated approval by July 7, 2026.
- eGFR analysis in Q3 2026 could be negative, delaying or preventing full approval.
- Competition from other IgAN therapies (e.g., Tarpeyo, Filspari) could limit market share.
- Clinical trial risks in expanded indications (membranous nephropathy, FSGS).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304986 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $33.12 awaiting T+1 | awaiting T+1 | — | $34.26 (+3.44%) |
|
Jun 2, 2026
12d ago
|
8-K
| $31.26 $31.27 | ▲ +0.03% | ▲ +0.75% | $34.26 (+9.60%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $31.26 $31.27 | ▲ +0.03% | ▲ +0.75% | $34.26 (+9.60%) |
|
May 7, 2026
5w ago
|
8-K
| $35.88 $36.19 | ▲ +0.86% | ▲ +0.03% | $34.26 (−4.52%) |
|
Feb 26, 2026
15w ago
|
8-K
| $42.35 $40.79 | ▼ −3.68% | ▼ −3.23% | $34.26 (−19.10%) |
|
Feb 23, 2026
16w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
16w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
16w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
16w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
16w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access